Cytokinetics, Incorporated has grown revenue 89% a year over three years and 3.2% a year over five. Revenue growth, 3-year annual rate: +89% (Biotechnology median +17%). Revenue growth, 5-year rate: +3.2%, growth has picked up over the last three years. Years of annual history on file: 27, FY1999 to FY2025, as filed.

CYTKCytokinetics, Incorporated

Healthcare

$62.93+29% 1Y

$62.93

$47.8352 weeks$84.88

Is it growing?

Mixed

Neither accelerating nor breaking down: operating margin widening (+7515.7 points), but revenue shrinking (−21% year on year).

1 good, 1 to watch, 1 without data

Revenue trend−21% in a year

Trailing-twelve-month revenue vs a year earlier, from the company's own filings. Five-year pace: +3% a year.

Margin direction+7515.7 points operating

Trailing-twelve-month operating margin, -2798.2% now against -10313.8% a year earlier.

All from SEC EDGAR, as of Jun 30, 2026.

Where this answer is blind. These are trailing numbers from the filings, not forecasts: an acquisition or a one-off year can flatter them, so check the quarters.

Is CYTK growing?

Cytokinetics, Incorporated has grown revenue 89% a year over three years and 3.2% a year over five.

+89%

Revenue growth, 3-year annual rate · Biotechnology median +17% · compounding fast · compounded from trailing twelve-month revenue

Revenue growth, 5-year rate: +3.2%
Revenue growth, 5-year rate · +89% over three · growth has picked up over the last three years
Years of annual history on file: 27
Years of annual history on file · FY1999 to FY2025, as filed

Details›